Former Chief Medical Officer · X4 Pharmaceuticals, Inc (XFOR)

Christopher Stevens

A named executive officer of X4 Pharmaceuticals in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,305,218

Salary $380,000Stock awards $0

FY2017: $657,537

3rd of 6 named executive officers at X4 Pharmaceuticals by FY2018 total.

6 named officers on file for X4 Pharmaceuticals, FY2018

Christopher Stevens’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how X4 Pharmaceuticals’s whole pay program stands against its peers

  • X4 Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XFOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 22, 2019 (DEF 14A).

Free

Get Christopher Stevens’s full pay file as a PDF — free

More than this page: up to 10 years of Christopher’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Christopher Stevens compensation by year

X4 Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as X4 Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$380,000$380,000
Bonus$159,600$0
Stock awards$0$0
Option awards$117,937$595,885
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$329,333
Total$657,537$1,305,218

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: X4 Pharmaceuticals, Inc DEF 14A filed May 22, 2019, accession 0001193125-19-154033, and prior-year filings. Open the filing on EDGAR.

How this page was built: the X4 Pharmaceuticals, Inc filed document, accession 0001193125-19-154033. Every figure is read from that document and cited to the page and table it appears in. Filed May 22, 2019.

$658K
$1.3M
FY17
FY18
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option9,882—$9.39
Option27,466—$4.00
Option50,000—$17.34

Per the Outstanding Equity Awards at Fiscal Year-End table in X4 Pharmaceuticals, Inc's FY2018 proxy; value at the fiscal year-end close, as the company printed it.

X4 Pharmaceuticals’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
René BCPSFormer President and Chief Executive Officer$3,358,949
Michael GrayFormer President, Chief Executive Officer and Chief Financial Officer$2,927,276
Christopher Stevens · this pageFormer Chief Medical Officer$1,305,218
David MantusFormer Chief Development Officer$1,074,885
Paula RaganPresident, Chief Executive Officer and Secretary$921,027
Adam MostafaChief Financial Officer and Treasurer$628,414

The full X4 Pharmaceuticals compensation record

free company brief

This page is one person within X4 Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are X4 Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Stevens's compensation dossier · One-time report. No refunds.